Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT950
- Development stage
- Preclinical
- Lead developer
- Phanes Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PT950 is a conditional T-cell engager (TCE) bispecific antibody developed by Phanes Therapeutics for the treatment of ovarian cancer. The molecule is designed to simultaneously target a tumor-associated antigen (TAA) expressed on malignant cells and the CD3 complex on T cells. The "conditional" nature of the antibody is engineered to ensure that T-cell activation occurs preferentially within the tumor microenvironment, which is intended to minimize systemic immune activation and improve the safety profile compared to traditional T-cell engagers. As of August 2025, PT950 is in the IND-enabling stage of development.
02
Targets
Beyond the preview
Go deeper on PT950.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT950.